Exchange: NASDAQ·Updated 04:38 PM EST

AGMB AgomAb Therapeutics NV - ADR

$5.46
$0.17
(3.02%)
Today
Closed $5.45
$0.01
(0.18%)
After Hours
Mkt Cap$276.77M
Vol183,990.00

About AGMB

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.
52

Neutral Sentiment

How do you feel about AGMB?

caracicatriz
$AGMB $PFE has increased its stake in $AGMB to 5%. I smell an acquisition attempt in the near future given the great Phase 2a results and cash war chest

Advertisement|Remove ads.